- Home
- PFO vs LUNG Comparison
PFO vs LUNG Comparison
Compare PFO & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFO
- LUNG
- Stock Information
- Founded
- PFO 1991
- LUNG 1995
- Country
- PFO United States
- LUNG United States
- Employees
- PFO N/A
- LUNG N/A
- Industry
- PFO Finance Companies
- LUNG Industrial Specialties
- Sector
- PFO Finance
- LUNG Health Care
- Exchange
- PFO Nasdaq
- LUNG Nasdaq
- Market Cap
- PFO 116.6M
- LUNG 124.0M
- IPO Year
- PFO N/A
- LUNG 2020
- Fundamental
- Price
- PFO $9.14
- LUNG $2.67
- Analyst Decision
- PFO
- LUNG Buy
- Analyst Count
- PFO 0
- LUNG 6
- Target Price
- PFO N/A
- LUNG $11.53
- AVG Volume (30 Days)
- PFO 31.8K
- LUNG 366.5K
- Earning Date
- PFO 01-01-0001
- LUNG 07-30-2025
- Dividend Yield
- PFO 6.51%
- LUNG N/A
- EPS Growth
- PFO N/A
- LUNG N/A
- EPS
- PFO N/A
- LUNG N/A
- Revenue
- PFO N/A
- LUNG $87,473,000.00
- Revenue This Year
- PFO N/A
- LUNG $18.02
- Revenue Next Year
- PFO N/A
- LUNG $18.17
- P/E Ratio
- PFO N/A
- LUNG N/A
- Revenue Growth
- PFO N/A
- LUNG 19.84
- 52 Week Low
- PFO $6.90
- LUNG $2.62
- 52 Week High
- PFO $8.51
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- PFO 59.24
- LUNG 33.53
- Support Level
- PFO $9.03
- LUNG $2.62
- Resistance Level
- PFO $9.17
- LUNG $3.52
- Average True Range (ATR)
- PFO 0.14
- LUNG 0.23
- MACD
- PFO 0.00
- LUNG 0.02
- Stochastic Oscillator
- PFO 95.69
- LUNG 13.46
About PFO Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated
Flaherty & Crumrine Prfd Income Oppo is the United States-based diversified, closed-end management investment company. Its primary investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.